Who is sponsoring NCT00546819?

NCT00546819 is sponsored by Merck Sharp & Dohme LLC.

What condition does NCT00546819 study?

NCT00546819 studies Herpes Zoster.

What drugs are being tested in NCT00546819?

Interventions: Zoster Vaccine, Live, Comparator: Placebo.

What is the status of NCT00546819?

NCT00546819 is currently COMPLETED.

Last reviewed 2017-03-14 · How we verify

A Phase IIb Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids

NCT00546819 Phase 2 COMPLETED Results posted

The purpose of the study was to assess the safety, tolerability, and immunogenicity of ZOSTAVAX™ in patients receiving chronic/maintenance corticosteroids.

Details

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 2
Status	COMPLETED
Enrolment	309
Start date	2007-10
Completion	2010-08

Conditions

Herpes Zoster

Interventions

Zoster Vaccine, Live
Comparator: Placebo

Primary outcomes

Number of Participants With Serious Adverse Events (SAE) — Up to 182 days postvaccination
A serious adverse event is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement.